JetFly
2020-06-21

$吉利德科学(GILD)$@正义创造力量: GILD: Vaccines Will Underwhelm, And Why Gilead Has A Substantially Larger Market Opportunity

7:04 am, Sat, Jun. 20, 2020, by Et al BioCapital

Summary

The complex immunogenicity of ** strongly suggests vaccines and antibody treatments are unlikely to deliver meaningful results.

We are unlikely to develop immunity to **, making it our newest endemic virus.

Antivirals are the best and most practical way to treat **.

Antivirals such as Gilead’s Remdesivir have a significantly bigger clinical need and market opportunity than is currently appreciated.

We estimate Gilead has a multi-year, multi-billion dollar opportunity with Remdesivir.

分享我的交易策略
交易策略分享,说一说自己在交易中的那些神操作吧,你的idea说不定价值百万!
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法